BNT324/DB-1311 showed encouraging antitumor activity and a manageable safety profile in a Phase 1/2a clinical trial in heavily pretreated patients with locally advanced or metastatic solid tumors, including small cell lung cancer (“SCLC”), non-small cell […]
PRINCETON, N.J., SHANGHAI and SUZHOU, China, Dec. 3, 2024 /PRNewswire/ — Duality Biologics (“DualityBio”), a clinical-stage biotech company focusing on the discovery and development of next-generation antibody-drug conjugate (ADC) therapeutics, today announced that it has […]
